Comparing the current results to its competitors, Anebulo Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2025 year on year by 0 %, slower than the combined decrease of the ANEB's competitors by -6.2 %, recorded in the same quarter.
Anebulo Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -82.43 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -82.43 %
Anebulo Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in the clinical biotechnology industry, competing with biotechnology and pharmaceutical companies, academic institutions, and public and private research organizations. Competitors engage in research and development of treatments for substance use disorders, seek patent protection and licensing revenues, and compete for skilled personnel. Some competitors are larger and better funded. Notable competitors include Aelis Farma, which is developing a medication based on a pregnenolone derivative to treat cannabis use disorders in collaboration with Indivior PLC. Additional competition arises from medical device, pharmaceutical, and biotechnology companies, universities, governmental entities, and other organizations entering the field, with competition expected to increase.
July 22, 2024
The growing acceptance and legalization of cannabis in various parts of the globe have led to a surge in consumption. However, individuals who experience cannabis-induced toxic effects due to overconsumption or exposure to high-potency strains may require medical intervention. Recognizing the urgent need for effective treatment options in this domain, Anebulo Pharmaceuticals has emerged as a leading player in developing novel therapies to alleviate acute cannabis-induced toxicity.Securing the NIDA grant is a testament to Anebulo s dedication and competence in tackling this relatively unaddressed medical issue. This multi-million-dollar grant will enable Anebulo Pharmaceuticals to conduct groundbreaking resea...
Publicly Traded Peers of Anebulo Pharmaceuticals Inc
Bioxcel Therapeutics Inc Share Performance
-65.69%
Over The Past 5 Days
Bioxcel Therapeutics Inc
Profile
BioXcel Therapeutics Inc. is a biopharmaceutical company that operates using an innovative business model. They utilize artificial intelligence (AI) and big data analytics to identify and develop novel therapies for targeted diseases with unmet medical needs. This approach allows them to leverage data-driven insights to expedite drug discovery and development, potentially increasing the efficiency and success rate of their drug candidates.
Bullfrog Ai Holdings Inc utilizes artificial intelligence technology to develop and provide advanced solutions for businesses. Their business model focuses on offering AI-powered products and services to help companies optimize their operations and decision-making processes.
Avadel Pharmaceuticals operates as a specialty pharmaceutical company, utilizing its proprietary drug delivery technology to develop and commercialize medications focused on improving patients' lives. They aim to address unmet medical needs by delivering innovative products and therapies in areas such as central nervous system disorders, sleep disturbances, and urology.
Artelo Biosciences Inc is a pharmaceutical company that focuses on developing novel therapeutics in the field of cannabinoid-based medicines. Their business model revolves around conducting research, developing proprietary formulations, and seeking regulatory approvals for their drug candidates. Through strategic partnerships and collaborations, they aim to bring innovative treatments to market, addressing unmet medical needs and enhancing patient outcomes.
Ardelyx Inc is a biopharmaceutical company that focuses on the development of novel, minimally-absorbed small molecules to treat gastrointestinal diseases. Their business model revolves around identifying specific needs within the gastrointestinal field and leveraging their research and development capabilities to create innovative therapeutic solutions. By partnering with other pharmaceutical companies and pursuing strategic collaborations, Ardelyx aims to bring its products to market and ultimately improve patient outcomes in the gastrointestinal space.
Sources:
Anebulo Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Anebulo Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
